These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 25170251)
1. Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery. Chimote G; Sreenivasan J; Pawar N; Subramanian J; Sivaramakrishnan H; Sharma S Drug Des Devel Ther; 2014; 8():1107-23. PubMed ID: 25170251 [TBL] [Abstract][Full Text] [Related]
2. Toxicity and anti-angiogenicity evaluation of Pak1 inhibitor IPA-3 using zebrafish embryo model. Jagadeeshan S; Sagayaraj RV; Paneerselvan N; Ghouse SS; Malathi R Cell Biol Toxicol; 2017 Feb; 33(1):41-56. PubMed ID: 27581547 [TBL] [Abstract][Full Text] [Related]
3. A systematical comparison of anti-angiogenesis and anti-cancer efficacy of ramucirumab, apatinib, regorafenib and cabozantinib in zebrafish model. Wu JQ; Fan RY; Zhang SR; Li CY; Shen LZ; Wei P; He ZH; He MF Life Sci; 2020 Apr; 247():117402. PubMed ID: 32035930 [TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic activity and mechanism of kaurane diterpenoids from Wedelia chinensis. Huang W; Liang Y; Wang J; Li G; Wang G; Li Y; Chung HY Phytomedicine; 2016 Mar; 23(3):283-92. PubMed ID: 26969382 [TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic activity of para-coumaric acid methyl ester on HUVECs in vitro and zebrafish in vivo. Zhang HZ; Li CY; Wu JQ; Wang RX; Wei P; Liu MH; He MF Phytomedicine; 2018 Sep; 48():10-20. PubMed ID: 30195867 [TBL] [Abstract][Full Text] [Related]
6. The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy. Tarallo V; De Falco S Int J Biochem Cell Biol; 2015 Jul; 64():185-9. PubMed ID: 25936669 [TBL] [Abstract][Full Text] [Related]
7. A systematic comparison of anti-angiogenesis efficacy and cardiotoxicity of receptor tyrosine kinase inhibitors in zebrafish model. Ma C; Wu Z; Wang X; Huang M; Wei X; Wang W; Qu H; Qiaolongbatu X; Lou Y; Jing L; Fan G Toxicol Appl Pharmacol; 2022 Sep; 450():116162. PubMed ID: 35830948 [TBL] [Abstract][Full Text] [Related]
8. Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials. Zhang C; Tan C; Ding H; Xin T; Jiang Y Curr Pharm Des; 2012; 18(20):2921-35. PubMed ID: 22571661 [TBL] [Abstract][Full Text] [Related]
9. Mammalian tumor xenografts induce neovascularization in zebrafish embryos. Nicoli S; Ribatti D; Cotelli F; Presta M Cancer Res; 2007 Apr; 67(7):2927-31. PubMed ID: 17409396 [TBL] [Abstract][Full Text] [Related]
10. Zebrafish (Danio rerio) embryo as a platform for the identification of novel angiogenesis inhibitors of retinal vascular diseases. Rezzola S; Paganini G; Semeraro F; Presta M; Tobia C Biochim Biophys Acta; 2016 Jul; 1862(7):1291-6. PubMed ID: 27085972 [TBL] [Abstract][Full Text] [Related]
11. A synthetic dl-nordihydroguaiaretic acid (Nordy), inhibits angiogenesis, invasion and proliferation of glioma stem cells within a zebrafish xenotransplantation model. Yang X; Cui W; Yu S; Xu C; Chen G; Gu A; Li T; Cui Y; Zhang X; Bian X PLoS One; 2014; 9(1):e85759. PubMed ID: 24454929 [TBL] [Abstract][Full Text] [Related]
12. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth. Gacche RN; Meshram RJ Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944 [TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053 [TBL] [Abstract][Full Text] [Related]
14. VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016). Peng FW; Liu DK; Zhang QW; Xu YG; Shi L Expert Opin Ther Pat; 2017 Sep; 27(9):987-1004. PubMed ID: 28621580 [TBL] [Abstract][Full Text] [Related]
15. Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy. Liu Y; Li Y; Wang Y; Lin C; Zhang D; Chen J; Ouyang L; Wu F; Zhang J; Chen L J Hematol Oncol; 2022 Jul; 15(1):89. PubMed ID: 35799213 [TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors. Cheng K; Liu CF; Rao GW Curr Med Chem; 2021; 28(13):2540-2564. PubMed ID: 32407259 [TBL] [Abstract][Full Text] [Related]
17. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future. Sharma PS; Sharma R; Tyagi T Curr Cancer Drug Targets; 2011 Jun; 11(5):624-53. PubMed ID: 21486218 [TBL] [Abstract][Full Text] [Related]
18. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling. Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875 [TBL] [Abstract][Full Text] [Related]
19. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. Le Tourneau C; Vidal L; Siu LL Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176 [TBL] [Abstract][Full Text] [Related]
20. In vivo Screening of Natural Products Against Angiogenesis and Mechanisms of Anti-Angiogenic Activity of Deoxysappanone B 7,4'-Dimethyl Ether. Chen K; Fan Y; Gu J; Han Z; Zeng H; Mao C; Wang C Drug Des Devel Ther; 2020; 14():3069-3078. PubMed ID: 32801645 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]